Monk and Herzog Hammer Out PARP Nuances in Ovarian Cancer
In our exclusive interview, Dr. Monk and Dr. Herzog discuss the importance of molecular testing in ovarian cancer and the utility of PARP inhibitor maintenance and treatment.
Welcome to OncLive On AirTM! I’m your host today, Jessica Hergert.
OncLive On AirTM is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Clovis Oncology, we passed the mic to Bradley J. Monk, MD, FACOG, FACS, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, Arizona Oncology, and Thomas Herzog, MD, a professor of obstetrics and gynecology and deputy director at University of Cincinnati Cancer Institute, to discuss the use of PARP Inhibitors in patients with BRCA-positive ovarian cancer.
In our exclusive interview, Monk and Herzog discussed the importance of molecular testing in ovarian cancer and the utility of PARP inhibitor maintenance and treatment.
